Tumor Treating Fields (TTFields) for Newly Diagnosed Glioblastoma in the Real World: A Systematic Review and Survival Meta-Analysis
Abstract
PURPOSE/OBJECTIVE(S)
Tumor Treating Fields (TTFields) are electric fields that exert forces on cancer cells, disrupting processes critical for cancer cell viability and tumor progression. TTFields therapy is FDA-approved for patients with newly diagnosed glioblastoma (GBM) on the basis of the randomized controlled EF-14 study (NCT00916409). Subsequent approvals and increased worldwide adoption of TTFields has led to the question of whether or not a consistent survival benefit has been observed in the real-world setting, and whether device usage has played a role.
MATERIALS/METHODS
PubMed, Embase, and the Cochrane Library were searched using pre-defined terms, to identify clinical studies (including comparative and single-cohort studies) evaluating overall survival (OS) in adult patients with GBM treated with TTFields therapy added to radiochemotherapy. The Cochran Q test was used to assess inter-study heterogeneity, and results were quantified using the Higgins I2 statistic. Data were pooled, and a survival curve created using a distribution-free random-effects method.
RESULTS
Records identified from the literature search were screened and distilled using pre-specified methods, down to 8 studies evaluating the clinical efficacy of TTFields therapy in newly diagnosed GBM (spanning diverse geographic regions). Six studies (reporting on a total of 1378 patients) compared the addition of TTFields therapy to standard of care (SOC) vs SOC alone, and were included in a pooled…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,378 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.